NDA 214876 · Glaxosmithkline
Zejula
Niraparib Tosylate · Oral
OrphanLast checked: Nov 19, 2026Latest source record: Mar 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Apr 26, 2023
Approved uses
2
Original approval plus efficacy supplements
Registered trials
208
25 Phase 3, 37 recruiting
FAERS reports
22,176
14,713 serious, 1,448 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 28, 2026.
ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: • for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: o a deleterious or suspected deleterious BRCA mutation, and/or o genomic instability. Select patients for therapy based on an FDA‑authorized companion diagnostic for ZEJULA. ( 1.1 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA‑authorized companion diagnostic for ZEJULA. ( 1.2 , 2.1 ) 1.1 First-Line Maintenance Treatment of HRD-Positive Advanced Ovarian Cancer ZEJULA is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA ‑ authorized companion diagnostic for ZEJULA [see Dosage and Administration ( 2.1 )] . 1.2 Maintenance Treatment of Recurrent Germline BRCA -Mutated Ovarian Cancer ZEJULA is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated (g...
Mechanism: Niraparib is an inhibitor of PARP enzymes, including PARP-1 and PARP-2, that play a role in DNA repair. In vitro studies have shown that niraparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis, and cell death. Increased niraparib‑induced cytotoxicity was observed in tumor cell lines with or without deficiencies in BRCA1/2 . Niraparib decreased tumor growth in mouse xenograft models of human cancer cell lines with deficiencies in BRCA1/2 and in human patient-derived xenograft tumor models...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 18, 2025 Supplement 3 · Efficacy OrphanLabelLetterReview
- Apr 26, 2023 Original approval · Type 3 - New Dosage Form OrphanLabelLetterReview
3 products under this application
- ZEJULA · NIRAPARIB TOSYLATE EQ 200MG BASE · TABLET, ORAL · Prescription
- ZEJULA · NIRAPARIB TOSYLATE EQ 300MG BASE · TABLET, ORAL · Prescription
- ZEJULA · NIRAPARIB TOSYLATE EQ 100MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Niraparib" as an intervention, any sponsor and status, largest first.
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
Oslo University HospitalAcademic, hospital or other
NCT04817956 · 3,000 participants (planned) · Start Apr 1, 2021 · Primary completion Mar 30, 2040
Drug: Atezolizumab · For: Cancer Metastatic
Sites: Ålesund, Norway; Bergen, Norway; Bodø, Norway · 17 sites in all
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
- A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian CancerPivotal-lookingActive, not recruiting
Tesaro, Inc.GSK (GSK)
NCT03602859 · 1,400 participants · Start Oct 11, 2018 · Primary completion Oct 31, 2024
Drug: Niraparib; Dostarlimab (TSR-042) and 3 more · For: Ovarian Neoplasms; Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Sites: Anchorage, Alaska; Phoenix, Arizona; Tucson, Arizona · 182 sites in all
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03768063 · 1,000 participants (planned) · Start Feb 28, 2019 · Primary completion Jul 5, 2028
Drug: Atezolizumab; Bevacizumab and 14 more · For: Cancer
Sites: Aurora, Colorado; Trumbull, Connecticut; Boston, Massachusetts · 80 sites in all
- Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian CancerPivotal-lookingRecruiting
AGO Study GroupAcademic, hospital or other
NCT05009082 · 970 participants (planned) · Start Sep 13, 2022 · Primary completion Dec 2028
Drug: Carboplatin; Paclitaxel and 2 more · For: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Sites: Amberg, Germany; Augsburg, Germany; Bad Homburg, Germany · 65 sites in all
- Personalized Medicine for Advanced Biliary Cancer PatientsPivotal-lookingRecruiting
UNICANCERAcademic, hospital or other
NCT05615818 · 800 participants (planned) · Start Jul 18, 2024 · Primary completion Jun 2027
Drug: Futibatinib; Ivosidenib and 8 more · For: Biliary Tract Neoplasms
Sites: Brussels, Belgium; Edegem, Belgium; Leuven, Belgium · 69 sites in all
- A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial CancerPivotal-lookingActive, not recruiting
Tesaro, Inc.GSK (GSK)
NCT03981796 · 785 participants · Start Jul 18, 2019 · Primary completion Nov 26, 2026
Drug: Dostarlimab; Placebo matching dostarlimab and 4 more · For: Neoplasms
Sites: Phoenix, Arizona; Scottsdale, Arizona; Tucson, Arizona · 169 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea5,789
- fatigue5,237
- platelet count decreased4,145
- constipation4,108
- insomnia2,844
- blood pressure increased2,458
- headache2,372
- off label use2,250
- vomiting2,037
- decreased appetite1,884
- asthenia1,858
- product dose omission issue1,855
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2016 | 4 |
| 2017 | 1,323 |
| 2018 | 3,278 |
| 2019 | 1,319 |
| 2020 | 3,087 |
| 2021 | 3,231 |
| 2022 | 3,628 |
| 2023 | 2,967 |
| 2024 | 2,062 |
| 2025 | 878 |
| 2026 | 398 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zejula (Niraparib Tosylate)
2024 spending
$224M
Beneficiaries
2,016
11,448 claims
Per beneficiary
$111,182
$598.84 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $138,638,865 |
| 2021 | $152,013,598 |
| 2022 | $154,728,383 |
| 2023 | $161,500,239 |
| 2024 | $224,142,913 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Monk BJ, Barretina-Ginesta MP, Pothuri B, et al. · Ann Oncol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
Chi KN, Rathkopf D, Smith MR, et al. · J Clin Oncol 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
González-Martín A, Pothuri B, Vergote I, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Multicenter Study
- Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance.
Wu W, Klockow JL, Zhang M, et al. · Pharmacol Res 2021 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.
Attard G, Agarwal N, Graff JN, et al. · Nat Med 2025 · Clinical Trial, Phase III, Multicenter Study
- Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors.
Luo Y, Xia Y, Liu D, et al. · Cell 2024 · Clinical Trial, Phase II
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.